Ocugen, Inc. (OCGN)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Ocugen, Inc. (OCGN)
Go deeper and ask any question about OCGN
Company Performance
Current Price
as of Sep 13, 2024$1.21
P/E Ratio
N/A
Market Cap
$348.31M
Description
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Metrics
Overview
- HQMalvern, PA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerOCGN
- Price$1.21+0.83%
Trading Information
- Market Cap$348.31M
- Float98.50%
- Average Daily Volume (1m)3,437,685
- Average Daily Volume (3m)5,465,425
- EPS-$0.18
Company
- Revenue$3.56M
- Rev Growth (1yr)N/A
- Net Income-$15.28M
- Gross Margin49.34%
- EBITDA Margin-1,303.33%
- EBITDA-$14.87M
- EV$390.07M
- EV/Revenue109.45
- P/EN/A
- P/S87.37
Documents
SEC Filings
Earnings Calls
Factset Street Account